Compare TBI & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBI | KRRO |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.9M | 150.0M |
| IPO Year | 1995 | 2019 |
| Metric | TBI | KRRO |
|---|---|---|
| Price | $4.59 | $13.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $6.00 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 305.8K | 171.5K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.39 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,392,000.00 |
| Revenue This Year | $6.25 | N/A |
| Revenue Next Year | $3.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $3.18 | $5.20 |
| 52 Week High | $7.78 | $55.89 |
| Indicator | TBI | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 65.84 | 57.22 |
| Support Level | $4.57 | $12.98 |
| Resistance Level | $5.56 | $15.00 |
| Average True Range (ATR) | 0.29 | 1.02 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 93.24 | 50.34 |
TrueBlue Inc is a provider of specialized workforce solutions that connect employers with talent. Its reportable segments include PeopleReady, which provides blue-collar contingent staffing and delivers on-demand and skilled labor across industries such as construction, transportation, retail, hospitality, and energy. The PeopleManagement segment offers contingent labor and outsourced industrial workforce solutions, mainly on-site at client facilities, through its OnSite and Centerline operations, focusing on workforce management and commercial driver services. PeopleSolutions delivers services focused on professional and specialized talent acquisition, as well as workforce management and compliance. The company generates the majority of its revenue from the PeopleReady segment.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.